Amiodarone dosing: a proposal based on its pharmacokinetics.

[1]  G. Tognoni,et al.  Clinical Pharmacokinetics of Amiodarone , 1984, Clinical pharmacokinetics.

[2]  J. Alpert,et al.  Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience. , 1983, American heart journal.

[3]  M. Anastasiou-Nana,et al.  Pharmacokinetics of amiodarone after intravenous and oral administration. , 1982, International journal of clinical pharmacology, therapy, and toxicology.

[4]  N. El-Sherif,et al.  Hypotensive Action of Commercial Intravenous Amiodarone and Polysorbate 80 in Dogs , 1982, Journal of cardiovascular pharmacology.

[5]  K. Nademanee,et al.  Amiodarone kinetics after oral doses , 1982, Clinical pharmacology and therapeutics.

[6]  P. Brugada,et al.  A comparison of the electrophysiological effects of intravenous and oral amiodarone , 1982 .

[7]  E. Riva,et al.  Pharmacokinetics of Amiodarone in Rats , 1982, Journal of cardiovascular pharmacology.

[8]  D. Holt,et al.  Intravenous amiodarone; An effective anti-arrhythmic agent , 1982 .

[9]  J. Kaski,et al.  Long‐term Management of Sustained, Recurrent, Symptomatic Ventricular Tachycardia with Amiodarone , 1981, Circulation.

[10]  G. Tucker,et al.  Lignocaine and indocyanine green kinetics in patients following myocardial infarction. , 1980, British journal of clinical pharmacology.

[11]  A. Camm,et al.  Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. , 1980, British heart journal.

[12]  G. Nau,et al.  Clinical efficacy of amiodarone as an antiarrhythmic agent. , 1976, The American journal of cardiology.

[13]  M. B. Rosenbaum,et al.  Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. , 1974, The American journal of cardiology.